CURE’s kidney cancer page is an extensive resource of cancer information featuring the latest kidney cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on kidney cancer.
November 17th 2016
Cabometyx was proved to be superior to Sutent, reducing rates of disease progression or death for patients with metastatic RCC, according to a recent trial.
October 11th 2016
In a recent phase 2 trial, Cabometyx showed longer progression-free survival than Sutent in patients with metastatic kidney cancer.
October 9th 2016
After going through the "Dark Ages," we're approaching the "Golden Age" of kidney cancer care, with more options available than ever, says James Hsieh.
October 3rd 2016
There have been some exciting advances in using immunotherapy to treat GU malignancies such as kidney and bladder cancer. CURE sat down with Elizabeth Plimack, M.D. to discuss them.
September 23rd 2016
The treatment landscape for advanced kidney cancer has changed dramatically over the past few years, with several targeted drugs and an immunotherapy approved by the FDA.
September 23rd 2016
Ten years ago, patients with advanced RCC had very few treatment options, yet today, there are multiple therapeutic strategies and more in the pipeline for this not-very-common tumor type, writes our editor-in-chief, Debu Tripathy.
September 21st 2016
While many new treatment options have been introduced for kidney cancer in recent years, the question of how to sequence them is still being debated.
September 16th 2016
A recent study showed a correlation between higher body mass index and survival in some patients with kidney cancer.
September 14th 2016
Most people don't know much about kidney cancer at the time of their diagnosis. The Kidney Cancer Association wants to change that.
August 15th 2016
Jorge Garcia offers insight about the benefits of Cabometyx and the drug's impact on RCC.
August 13th 2016
Randy F. Sweis talks to CURE about the future of treatment for GU cancers.
August 4th 2016
A recent phase 3 study showed that Sutent extended disease-free survival for patients with renal cell carcinoma.
July 6th 2016
Sumanta K. Pal weighs in on a new drug combination that is showing promise for patients with RCC who progressed on Cabometyx (cabozantinib) and Opdivo (nivolumab).
June 24th 2016
The treatment paradigm in renal cell carcinoma (RCC) has expanded over recent months to include three practice-changing agents in the second-line setting.
June 22nd 2016
Not only is Opdivo changing the way RCC is being treated, but the immunotherapy is also here to stay, according to David F. McDermott.
June 10th 2016
Previously treated patients with advanced renal cell carcinoma saw a higher overall survival rate with Cabometyx when compared to those on Afinitor, according to a phase 3 study.
June 6th 2016
In the longest follow-up of an anti-PD-1 immunotherapy in RCC, about one-third of the patients treated with single-agent Opdivo are still alive four and five years later.
June 3rd 2016
What are the next steps for immunotherapy in RCC? CURE spoke with Mark Ball to find out.
May 14th 2016
After a phase 2 study, Lenvima and Afinitor gained FDA approval for the treatment of renal cell carcinoma.
May 9th 2016
“This is a small-site, single-arm study, but these preliminary data are encouraging,” says lead study author Roberto Pili. “It suggests that this combination of an HDAC inhibitor can induce a greater benefit with an immunotherapy — in this case, IL-2.”
May 9th 2016
Despite advances in treatment for bladder cancer and RCC, there is still an unmet need for navigating biomarkers that will offer insight as to which patients will respond best to treatment.
May 6th 2016
“There are a lot of drugs, many targets, and still no cures,” says Figlin. “There is still an unmet need, despite the plethora of agents that have been approved in this space.”
April 11th 2016
As treatments for kidney cancer continue to evolve, oncologists, surgeons and patients are faced with a number of questions.
April 8th 2016
The field of immunotherapy has been revitalized thanks to the approval of checkpoint inhibitors, and according to Mario Sznol, this could prove beneficial to patients with RCC.
March 8th 2016
The Kidney Cancer Association was part of the force behind the many kidney cancer advancements in the past decade, but they won't stop there.
February 19th 2016
New pathways for secondary-line treatment are coming available to patients with advanced renal cell carcinoma.
February 4th 2016
Cometriq elicited a statistically significant improvement in survival compared with Afinitor as a treatment for patients with advanced renal cell carcinoma following progression on one prior therapy.
January 9th 2016
Cometriq significantly improved progression-free survival versus Afinitor in patients with renal cell carcinoma regardless of the degree of metastases, type or number of prior treatments, or patient risk status.
November 24th 2015
The approval was based on an extension in overall survival (OS) in the CheckMate-025 trial.